期刊文献+

2004年和1973年世界卫生组织肿瘤分级预测局限浸润性膀胱癌复发价值的比较 被引量:2

Prognostic significance of the 2004 WHO classification compared with the 1973 WHO classification for organ-confined invasive bladder cancer
原文传递
导出
摘要 目的比较2004年和1973年WHO肿瘤分级预测局限浸润性(T分期≤pT2b)膀胱尿路上皮癌行根治性膀胱切除术后肿瘤复发概率的价值。方法回顾分析2000年2月至2011年8月具有完善随访结果的173例局限浸润性膀胱尿路上皮癌患者的临床及随访资料。采用Kaplan—Meier法和Log—rank检验评估无复发生存率(RFS);Cox比例风险模型进行单因素及多因素分析评估膀胱癌各传统预后因素(肿瘤分期、分级,淋巴结状况,淋巴血管肿瘤浸润情况,术前。肾积水,是否纯尿路上皮癌)对RFS的影响。结果患者5年RFS为84.7%。Cox分析显示,采用2004年WHO分级时,淋巴结阳性(RR=4.573,95%CI:1.469—14.237)、肿瘤分级(RR=9.993,95%CI:1.325~75.390)、术前肾积水(RR=3.207,95%CI:1.209~8.508)是RFS的独立预测因素;采用1973年WHO分级时,淋巴结阳性(RR=9.484,95%CI:3.450~26.074)和淋巴血管肿瘤浸润(RR=3.009,95%CI:1.062~8.526)是RFS的独立预测因素。结论2004年WHO分级作为RFS的独立预测因素,较1973年WHO分级更适用于T2b期以下局限浸润性膀胱癌,但仍需要进一步的前瞻性研究以证实其预后预测作用。 Objective To compare the 2004 and 1973 WHO classifications for predicting tumor recurrence for organ-confined (T stage ≤ pT2b) invasive urothelial carcinoma of the bladder treated with radical cystectomy. Methods From February 2000 to August 2011, the 173 consecutive cases of organ- confined invasive urothelial carcinoma of the bladder were treated with radical cystectomy. The data of clinical and follow-up information was collected. The Kaplan-Meier plots with Log-rank test were used to estimate recurrence-free survival ( RFS ). Univariate and multivariate analysis using the Cox proportional hazard regression model were performed to evaluate the impact of any clinicopathological prognostic factors (tumor grade, tumor stage, lymph node status, lymphovascular invasion, preoperative hydronephrosis, and non-pure urothelial carcinoma) on RFS. Results The 5-year RFS was 84. 7% for the entire cohort. Univariate and multivariate analysis demonstrated that when using the 2004 WHO classification, lymph node status (RR =4. 573, 95% CI: 1. 469-14. 237), tumor grade (RR =9. 993, 95% CI: 1. 325-75. 390) and preoperative hydronephrosis ( RR = 3. 207, 95% CI: 1. 209-8. 508 ) presented independent predictors for RFS; while using the 1973 WHO system, lymph node status (RR = 9. 484, 95% CI: 3. 450-26. 074) and lymphovaseular invasion (RR = 3. 009, 95% CI: 1. 062-8. 526) were independent predictors. Conclusions The 2004 WHO classification, as an independent factor, is superior to the 1973 classification for predicting RFS in patients with organ-confined invasive bladder cancer treated with radical cystectomy. However, a further perspective study is needed to validate its role in prognosis.
出处 《中华外科杂志》 CAS CSCD 北大核心 2013年第6期538-541,共4页 Chinese Journal of Surgery
关键词 膀胱肿瘤 肿瘤分期 预后 Urinary bladder neoplasms Neoplasm staging Prognosis
  • 相关文献

参考文献18

  • 1Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin, 2009, 59: 225-249.
  • 2Pan CC, Chang YH, Chen KK, et al. Prognostic significance of the 2004 WHO/ISUP classification for prediction of recurrence, progression, and cancer-specific mortality of non-muscle-invasive urothelial tumors of the urinary bladder: a clinicopathologic study of 1515 cases. Am J Clin Pathol, 2010, 133:788-795.
  • 3Burger M, van der Aa MN, van Oers JM, eta]. Prediction of progression of non muscle-invasive bladder cancer by WHO 1973 and2004 grading and by FGFR3 mutation status: a prospective study. Eur Urol, 2008, 54: 835-843.
  • 4May M, Brookman-Amissah S, Roigas J, et al. Prognostic accuracy of individual uropathologists in noninvasive urinary bladder carcinoma: a nmhicentre study comparing the 1973 and 2004 World Health Organisation classifications. Eur Urol, 2010, 57:850-858.
  • 5Otto W, Denzinger S, Fritsche HM, et al. The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU Int, 2011, 107:404-408.
  • 6Bircan S, Candir O, Serel TA. Comparison of WHO 1973, WHO/ISUP 1998, WHO 1999 grade and combined scoring systems in evaluation of bladder carcinoma. Urol Int, 2004, 73 : 201-208.
  • 7Jordan AM, Weingarten J, Murphy WM. Transitional cell neoplasms of the urinm'y bladder. Can biologic potential be predicted fi'om histologic grading?. Cancer, 1987, 60: 2766- 2774.
  • 8Kaubisch S, Lum BL, Reese J, et al. Stage T1 bladder cancer: grade is the primary determinant for risk of muscle invasion. J Urol, 1991, 146: 28-31.
  • 9Jimenez RE, Gheiler E, Oskanian P, et al. Grading the invasive component of urothelial carcinoma of the bladder and its relationship with progression-free survival. Am J Surg Pathol, 2000, 24 : 980-987.
  • 10Cheng L, Neumann RM, Weaver AL, et al. Grading and staging of bladder carcinoma in transurethral resection specimens. Correlation with 105 matched cystectomy specimens. Am J Clin Pathol, 2000,113:275-279.

同被引文献33

  • 1那彦群,叶章群,孙颖浩,等.中国泌尿外科疾病诊断治疗指南(2014版)[M].北京:人民卫生出版社,2014:528.
  • 2Siegel R, Ma J, Zou Z, gt al. Cancer statistics, 2014[J]: CA: a Cancer Journal for Clinicians, 2014, 64(1): 9-29.
  • 3Sherif A, Rintala E, Mestad O, et al. Neoadjuvant cisplatin- methotrexate chemotherapy for invasive bladder cancer-Nordic cystectomy trial 2[J]. Scandinavian Journal of Urology and Nephrology, 2002, 36(6): 419-425.
  • 4Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer [J]. The New England Journal of Medicine, 2003, 349(9): 859-866.
  • 5Martinez-Pineiro JA, Gonzalez Martin M, Arocena F, et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase HI study[J]. The Journal of Urology, 1995, 153(3 Pt 2): 964-973.
  • 6Wallace DM, Raghavan D, Kelly KA, et al. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive mmsitional cell carcinoma of the bladder [J]. British Journal of Urology, 1991, 67(6): 608-615.
  • 7Scosyrev E, Messing EM, van Wijngaarden E, et al. Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder [J]. Cancer, 2012, 118(1): 72-81.
  • 8Kitagawa Y, Izumi K, Miwa S, et al. Retrospective analysis of the efficacy of two cycles of M-VAC neoadjuvant chemotherapy followed by radical cystectomy for muscle-invasive bladder cancer [J]. Anticancer Research, 2013, 33(10): 4497-4503.
  • 9Kitamura H, Tsukamoto T, Shibata T, et al. Randomised phase HI study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine end cisplatin followed by radical cystectomy compared with radical cystectomy alone for musele-invasive bladder cancer: Japan Clinical Ontology Group Study JCOG0209[J]. Annals of Ontology: Official Journal Of the European Society for Medical Oncology/ESMO, 2014, 25(6): 1192-1198.
  • 10E1-Geheni F, North S, Ghosh S, et al. Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience[J]. Can Urol Assoe J, 2014, 8(3/4): e287-293.

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部